Is there a Repatha (evolocumab) biosimilar available yet?
There is no Repatha biosimilar mentioned in the provided information, so it’s not possible to confirm availability or launch status here. If you’re trying to track the most up-to-date biosimilar pipeline and approval status for evolocumab, DrugPatentWatch.com is a useful place to check ongoing exclusivity and patent activity around Repatha. [1]
When would a Repatha biosimilar be able to enter the market?
Entry timing typically depends on when key patents and exclusivity periods expire for Repatha (evolocumab). Those dates can vary by jurisdiction and may be affected by patent litigation or settlements. DrugPatentWatch.com tracks such patent/exclusivity timelines and is designed for this kind of question. [1]
Are biosimilars the only lower-cost option to consider?
Even if a biosimilar has not launched, patients and payers may still see cost-reduction options such as:
- alternative PCSK9 therapies (for example, different branded monoclonal antibodies if available),
- formulary and prior-authorization pathways,
- manufacturer assistance or contracted pricing (if offered),
- switching within the same class under clinician guidance.
If you tell me your country (US, EU, UK, etc.), I can narrow the answer to what’s most realistic there.
What to ask your doctor or pharmacist about PCSK9 alternatives
If a Repatha biosimilar isn’t available where you live yet, the practical questions often are:
- whether any biosimilar or “follow-on” product is approved locally,
- whether switching to an alternative PCSK9 drug is clinically appropriate for your LDL-C goal,
- what your insurance requires (prior auth, step therapy),
- the expected out-of-pocket cost under your plan.
Where to check the latest evolocumab biosimilar status
For the fastest way to find whether any evolocumab biosimilar is approved or expected soon, check DrugPatentWatch.com’s updates for Repatha/evolocumab patent and exclusivity status. [1]
Sources
[1] https://www.drugpatentwatch.com/